RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
HHLA2 在实体瘤中的重要性——文献综述
英文原题：The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
查看英文原题
The Importance of HHLA2 in Solid Tumors-A Review of the Literature.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症免疫治疗是医学中一个快速发展的领域，旨在利用宿主的免疫机制来抑制和消除癌细胞。靶向 CTLA-4、PD-1 及其配体 PD-L1 的抗体被用于多种癌症治疗。
然而，研究最为深入的靶向 PD-1/PD-L1 通路存在许多局限性，多种恶性肿瘤对其效应具有抵抗性。人内源性逆转录病毒-H 长末端重复序列关联蛋白 2（HHLA2，又称 B7H5/B7H7/B7y）是 B7 家族中已知最新的分子。HHLA2/TMIGD2/KIRD3DL3 是调节免疫应答的关键通路之一。近期研究表明，HHLA2 在调节免疫系统方面具有双重效应。HHLA2 与 TMIGD2 的结合通过 AKT 依赖性信号级联诱导 T 细胞生长和细胞因子产生。另一方面，HHLA2 与 KIR3DL3 的结合导致 T 细胞抑制，并介导肿瘤对 NK 细胞的抵抗。本综述旨在总结关于 HHLA2 的新信息，重点关注 HHLA2/KIR3DL3/TMIGD2 通路的免疫学机制和临床特征，以及在恶性肿瘤治疗潜在策略背景下的意义。
展开英文摘要原文
Cancer immunotherapy is a rapidly developing field of medicine that aims to use the host's immune mechanisms to inhibit and eliminate cancer cells. Antibodies targeting CTLA-4, PD-1, and its ligand PD-L1 are used in various cancer therapies.
However, the most thoroughly researched pathway targeting PD-1/PD-L1 has many limitations, and multiple malignancies resist its effects. Human endogenous retrovirus-H Long repeat-associating 2 (HHLA2, known as B7H5/B7H7/B7y) is the youngest known molecule from the B7 family. HHLA2/TMIGD2/KIRD3DL3 is one of the critical pathways in modulating the immune response. Recent studies have demonstrated that HHLA2 has a double effect in modulating the immune system.
The connection of HHLA2 with TMIGD2 induces T cell growth and cytokine production via an AKT-dependent signaling cascade. On the other hand, the binding of HHLA2 and KIR3DL3 leads to the inhibition of T cells and mediates tumor resistance against NK cells. This review aimed to summarize novel information about HHLA2, focusing on immunological mechanisms and clinical features of the HHLA2/KIR3DL3/TMIGD2 pathway in the context of potential strategies for malignancy treatment.
论文信息
- 作者
- Kula A、Koszewska D、Kot A、Dawidowicz M、Mielcarska S、Waniczek D、Świętochowska E
- 第一作者单位
- Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland.Poland
- 通讯作者单位
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 19 Jordana, 41-800 Zabrze, Poland.Jordan
- 文献类型
- 综述
- 期刊
- Cells2024 May 7
- 原文标识
- PubMed 38786018 · DOI 10.3390/cells13100794
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →